Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
| Revenue (TTM) | $2.44B |
| Gross Profit (TTM) | $2.81B |
| EBITDA | $1.56B |
| Operating Margin | 100.30% |
| Return on Equity | 13.80% |
| Return on Assets | 5.54% |
| Revenue/Share (TTM) | $5.67 |
| Book Value | $15.53 |
| Price-to-Book | 3.72 |
| Price-to-Sales (TTM) | 13.77 |
| EV/Revenue | 13.6 |
| EV/EBITDA | 19.54 |
| Quarterly Earnings Growth (YoY) | 23.20% |
| Quarterly Revenue Growth (YoY) | 11.00% |
| Shares Outstanding | $443.27M |
| Float | $413.50M |
| % Insiders | 6.51% |
| % Institutions | 86.07% |
Volatility is currently expanding
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 4:00 p.m. ET.
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma's positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers.
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the better value opportunity right now?
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
